Skip to content

GALECTIN THERAPEUTICS INC

GALT

CIK 0001133416

← back to feed
Revenue (TTM)
—
Q1 May 2026
Net Income (TTM)
−$30.38M
+34.5% YoY Q1 May 2026
EPS Diluted (TTM)
−$0.48
+36.8% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
—
Q1 May 2026
Net Margin
—
Q1 May 2026
Free Cash Flow (TTM)
−$34.45M
Q1 May 2026
Cash
$14.11M
Q1 May 2026
Total Debt
—
Q1 May 2026
Shares Outstanding
65.86M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings